Shots:
- Sun Pharma has entered into a definitive agreement to acquire Organon, growing Sun Pharma’s Innovative Medicines business & supporting its entry into biosimilars as a top-10 global player
- As per the deal, Sun Pharma will acquire Organon for $14/share in an all‑cash transaction with an enterprise valuation of $11.75B; closing is expected in early 2027
- Sun Pharma will fund the acquisition using a combination of available cash & bank financing, with the deal structured as a merger in which Organon will survive through a subsidiary merger
Ref: Sun Pharma | Image: Organon | Press Release
Related News: Sun Pharma Reports US FDA’s sBLA Acceptance of Ilumya for Active Psoriatic Arthritis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
